Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.